

§ 82.2707a

prepared by extending the barium salt prepared from Ext. D&C Red No. 2 upon the substratum is “Ext. D&C Red No. 2—Barium Lake.”)

§ 82.2707a Ext. D&C Yellow No. 7.

The color additive Ext. D&C Yellow No. 7 shall conform in identity with specifications to the requirements of § 74.1707a(a)(1) and (b) of this chapter. Ext. D&C Yellow No. 7 is restricted to use in externally applied drugs and cosmetics.

PARTS 83–98 [RESERVED]

PART 99—DISSEMINATION OF INFORMATION ON UNAPPROVED/NEW USES FOR MARKETED DRUGS, BIOLOGICS, AND DEVICES

Subpart A—General Information

Sec.

99.1 Scope.

99.3 Definitions.

Subpart B—Information To Be Disseminated

99.101 Information that may be disseminated.

99.103 Mandatory statements and information.

99.105 Recipients of information.

Subpart C—Manufacturer’s Submissions, Requests, and Applications

99.201 Manufacturer’s submission to the agency.

99.203 Request to extend the time for completing planned studies.

99.205 Application for exemption from the requirement to file a supplemental application.

Subpart D—FDA Action on Submissions, Requests, and Applications

99.301 Agency action on a submission.

99.303 Extension of time for completing planned studies.

99.305 Exemption from the requirement to file a supplemental application.

Subpart E—Corrective Actions and Cessation of Dissemination

99.401 Corrective actions and cessation of dissemination of information.

99.403 Termination of approvals of applications for exemption.

21 CFR Ch. I (4–1–13 Edition)

99.405 Applicability of labeling, adulteration, and misbranding authority.

Subpart F—Recordkeeping and Reports

99.501 Recordkeeping and reports.

AUTHORITY: 21 U.S.C. 321, 331, 351, 352, 355, 360, 360c, 360e, 360aa–360aaa–6, 371, and 374; 42 U.S.C. 262.

SOURCE: 63 FR 64581, Nov. 20, 1998, unless otherwise noted.

Subpart A—General Information

§ 99.1 Scope.

(a) This part applies to the dissemination of information on human drugs, including biologics, and devices where the information to be disseminated:

(1) Concerns the safety, effectiveness, or benefit of a use that is not included in the approved labeling for a drug or device approved by the Food and Drug Administration for marketing or in the statement of intended use for a device cleared by the Food and Drug Administration for marketing; and

(2) Will be disseminated to a health care practitioner, pharmacy benefit manager, health insurance issuer, group health plan, or Federal or State Government agency.

(b) This part does not apply to a manufacturer’s dissemination of information that responds to a health care practitioner’s unsolicited request.

§ 99.3 Definitions.

(a) *Agency* or *FDA* means the Food and Drug Administration.

(b) For purposes of this part, a *clinical investigation* is an investigation in humans that tests a specific clinical hypothesis.

(c) *Group health plan* means an employee welfare benefit plan (as defined in section 3(1) of the Employee Retirement Income Security Act of 1974 (29 U.S.C. 1002(1))) to the extent that the plan provides medical care (as defined in paragraphs (c)(1) through (c)(3) of this section and including items and services paid for as medical care) to employees or their dependents (as defined under the terms of the plan) directly or through insurance, reimbursement, or otherwise. For purposes of this part, the term *medical care* means: